I think you mean the loss blew out by over 100%. Costs (expenses) went from $5.8M to $7.6M but included a non cash writedown of $2M. Without that, costs would have improved slightly from last year. Revenue, on the other hand went from $3.8M down to $2.9M due in part to $.6 R&D grant not being received in the reporting period. Sales revenue fell from $3M to $2.8M which aint great (but see @edshann 's post on that). Not trying to sugar coat anything here but they did re-iterate their guidance on $7.5M sales pipeline for the coming half. Still a super risky stock (IMO) but I will hold for the next haft yearly and reassess then.
VIV Price at posting:
2.6¢ Sentiment: Hold Disclosure: Held
